clinical trial · NCT03624010
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Hypertension Pulmonary Secondary Heart FailureRight Sided Heart Failure With Normal Ejection FractionHeart Failure With Normal Ejection FractionLevosimendan
brief summary
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
started
Apr 9, 2019
primary completion
Apr 25, 2023
completion
Apr 25, 2023
last updated
Apr 22, 2026
detailed description
This study will enroll PH-HFpEF patients that have completed a controlled levosimendan study. These patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
official title
Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol